Though lung cancer looks promising a partner is now needed.
ApexOnco Front Page
Recent articles
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
The recently unveiled conjugate DS3610a is to start phase 1.
A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
So who else could be interested in the oestrogen degrader?
After menin, the company tries again with farnesyl transferase.
The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
